TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Pharma Industrial, has received approval from the National Medical Products Administration to commence a Phase I clinical trial for FXS0887 Tablets, intended for the treatment of advanced malignant solid tumors. FXS0887 is an innovative small molecule drug that inhibits ATR kinase activity, demonstrating significant anti-tumor efficacy in preclinical studies, which positions the company to potentially enhance its standing in the oncology sector.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company based in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceutical products, with a market emphasis on innovative drugs and treatments.
Average Trading Volume: 6,907,858
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.52B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.